Dr Moyle is a lecturer in the UQ School of Pharmacy working in the areas of medicinal chemistry and chemical biology, investigating subunit vaccine development, and outcomes associated with histone post-translational modifications.
The Moyle lab is currently looking for students and postdoctoral fellows with an interest in i) subunit vaccine development; ii) delivery systems for peptide therapeutics; iii) targeted delivery systems; iv) studying the function of posttranslational modifications; v) delivery systems for oligonucleotide therapeutics (e.g. siRNA, shRNA, miRNA). If you are interested in working in any of these areas please feel free to contact Dr Moyle (firstname.lastname@example.org). Preference will be given to students and postdoctoral fellows who have their own funding.
Funding may be found from sources including:
3) NHMRC Postgraduate Scholarship (includes $1500/year consumables and $750 for conference travel)
4) Endeavour Scholarships (for overseas students)
5) UQ International Postgraduate Research Scholarships (need outstanding undergraduate performance and research papers)
6) Many countries have their own scholarship schemes to train students overseas, with some also offering research funding. This is well worth looking into.
the following are for Malaysian's:
Malaysia Ministry of Higher Education (MOHE) Scholarships
Maktab Amanah Rakyat (MARA)
the following are for Chinese:
There are also scholarships available from many non-government organisations. Examples include:
Other sources of scholarship information:
Dr Moyle Biosketch:
Dr Moyle received a PhD (Dec 2006) and a Bachelor of Pharmacy (Hons I) (Dec 2001) from The University of Queensland (UQ); graduated from the Pharmaceutical Society of Australia pre-registration pharmacist-training course (Nov 2002); and is registered with the Pharmacy Board of Australia. He currently works as a lecturer in the School of Pharmacy.
Dr Moyle works in the fields of medicinal chemistry and chemical biology, investigating subunit vaccine development, and outcomes associated with histone post-translational modifications. During his PhD, Dr Moyle developed methods that enabled the synthesis of pure, lipid adjuvanted peptide vaccines, using advanced chemical ligation techniques. In addition, the conjugation of mannose to combined prophylactic/therapeutic human papillomavirus type-16 vaccines, to target dendritic cells, was demonstrated to significantly improve vaccine anti-tumour activity (PM2). This work, conducted with leading researchers at the QIMR Berghofer Medical Research Institute (Prof Michael Good & Dr Colleen Olive), established Dr Moyle's national and international profile in the field of vaccine development, resulting in 11 peer reviewed papers, including top journals in the field (J Med Chem; J Org Chem), as well as 6 review articles and 2 invited book chapters.
Dr Moyle recently worked in the laboratory of one of the world's premier chemical biologists, Professor Tom Muir (the Rockefeller University, NY, USA). During this time he developed an extensive knowledge of techniques for protein expression, bioconjugation, bioassays, and proteomics, which represent an essential skill set required for this proposal. As part of this work, Dr Moyle developed novel synthetic routes to generate site-specific ADP-ribose conjugated peptides and proteins. This research was hailed as a major breakthrough in the field, leading to several collaborations, and an exemplary publication in the prestigious chemistry journal JACS (PM1). This vast body of work identified the enzyme (PARP10) responsible for mono-ADP-ribosylation of histone H2B, and demonstrated interactions between this modification and several proteins, including BAL, which is associated with B cell lymphomas. In addition, a number of robust chemical methods were developed to enable the synthesis of a complete library of methyl-arginine containing histones, which were incorporated into synthetic chemically-defined chromatin to investigate the site-specific effects of arginine methylation on histone acetylation. This work led to a collaboration with colleagues at Rockefeller to investigate the effects of histone arginine methylation on transcription.